Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
Viridian Therapeutics Inc VRDN
$20.47
▼ -0.92%
($-0.19)
Open
$20.75
Prev Close
$20.66
Day Range
$20.16 – $21.01
52W Range
$13.18 – $34.29
Market Cap
$2.09B
Beta
1.09
EPS (TTM)
$-3.90
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-06-18 |
| Shares Out. | 110,430,000 |
| Website | viridiantherapeutics.com/ ↗ |
| Phone | 16172724600 |
| Employees | 252 |
| Revenue | $284,000 |
| Gross Profit | $284,000 |
| Net Income | -$127.1M |
| Free Cash Flow | -$335.0M |
| Total Assets | $1.10B |
| Total Liabilities | $435.1M |
| Equity | $662.1M |
About Viridian Therapeutics Inc
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics Inc is a publicly traded company under the ticker symbol VRDN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
23 analysts (2026-09-01)